Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Marek Krzyżanowski"'
Autor:
Elżbieta Grześk, Marek Krzyżanowski, Michał Wiciński, Wioleta Stolarek, Michał Kasprzak, Daniel Rogowicz, Grzegorz Grześk
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 5396, p 5396 (2021)
Journal of Clinical Medicine
Volume 10
Issue 22
Journal of Clinical Medicine
Volume 10
Issue 22
Background: Carbamazepine (CBZ) is a first-generation anticonvulsant drug. Hence, in certain cases, therapeutic drug monitoring (TDM) supports pharmacotherapy. Methods: The presented research was based on a retrospective analysis including 710 ambula
Autor:
Grzegorz Grześk, Wioleta Stolarek, Marek Krzyżanowski, Katarzyna Szadujkis-Szadurska, Michał Kasprzak, Michał Wiciński, Elżbieta Grześk
Publikováno v:
Pharmacological Reports. 70:184-189
Background Digoxin is the oldest drug used in the pharmacotherapy of heart failure (HF). However, digoxin remains an important therapeutic option for patients with persistent symptoms of HF occurring despite the implementation of standard pharmacothe
Autor:
A.T. Sinjab, Marek Krzyżanowski, Elżbieta Grześk, Grzegorz Grześk, Bartosz Malinowski, Michał Wiciński, Katarzyna Szadujkis-Szadurska, J. Dzięcioł, Dorota Bylina, Anna Czeczuk, Agnieszka Michalska
Publikováno v:
Polish Journal of Veterinary Sciences. 16:293-297
The aim of the study was to assess the impact of modulating factors on vascular smooth muscle cells reactivity. Vascular resistance was induced by the administration of increasing concentrations of imidazole. The experiments were performed on isolate
Autor:
Eliano Pio Navarese, Marek Koziński, Elzbieta Grzesk, Jolanta M. Siller-Matula, Marek Krzyżanowski, Fausto Castriota, Grzegorz Grzesk, Aldona Kubica, Jacek Kubica
Publikováno v:
Thrombosis Research. 130:65-69
Introduction Off-target effects of novel antiplatelet agents due to their potential clinical benefits are currently an area of intensive investigation. We aimed to compare the effects of different P2Y12 antagonists on the reactivity of vascular smoot